These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 38744175)

  • 1. Advancements in neoadjuvant immune checkpoint inhibitor therapy for locally advanced head and neck squamous Carcinoma: A narrative review.
    Li J; Luo Z; Jiang S; Li J
    Int Immunopharmacol; 2024 Jun; 134():112200. PubMed ID: 38744175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Less is more: Exploring neoadjuvant immunotherapy as a de-escalation strategy in head and neck squamous cell carcinoma treatment.
    Cao LM; Zhong NN; Chen Y; Li ZZ; Wang GR; Xiao Y; Liu XH; Jia J; Liu B; Bu LL
    Cancer Lett; 2024 Aug; 598():217095. PubMed ID: 38964728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
    Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
    Wang H; Zhao Q; Zhang Y; Zhang Q; Zheng Z; Liu S; Liu Z; Meng L; Xin Y; Jiang X
    Front Immunol; 2021; 12():652054. PubMed ID: 34305889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the efficacy and safety of different neoadjuvant immunotherapy combinations in locally advanced HNSCC: a systematic review and meta-analysis.
    Liu C; Li M; Liu X; Shi T; Wang Y; Sui C; Zhang W; Wang B
    Front Immunol; 2024; 15():1467306. PubMed ID: 39267732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for head and neck squamous cell carcinoma: current status and perspectives.
    Daste A; Larroquette M; Gibson N; Lasserre M; Domblides C
    Immunotherapy; 2024 Feb; 16(3):187-197. PubMed ID: 38126161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of neoadjuvant and definitive immunotherapy in locally advanced head and neck squamous cell carcinoma.
    Nindra U; Hurwitz J; Forstner D; Chin V; Gallagher R; Liu J
    Cancer Med; 2023 May; 12(10):11234-11247. PubMed ID: 36934434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
    Cohen EEW; Bell RB; Bifulco CB; Burtness B; Gillison ML; Harrington KJ; Le QT; Lee NY; Leidner R; Lewis RL; Licitra L; Mehanna H; Mell LK; Raben A; Sikora AG; Uppaluri R; Whitworth F; Zandberg DP; Ferris RL
    J Immunother Cancer; 2019 Jul; 7(1):184. PubMed ID: 31307547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive capacity of immune-related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma.
    Alnemri AE; Tekumalla S; Moroco AE; Vathiotis I; Tuluc M; Gargano S; Zhan T; Cognetti DM; Curry JM; Argiris A; Linnenbach A; South AP; Harshyne LA; Johnson JM; Luginbuhl AJ
    Cancer Med; 2024 Jun; 13(11):e7370. PubMed ID: 38847087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant immunotherapy for head and neck squamous cell carcinoma.
    Kürten CHL; Ferris RL
    Laryngorhinootologie; 2024 May; 103(S 01):S167-S187. PubMed ID: 38697147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current landscape of immunotherapy trials in locally advanced and high-risk head and neck cancer.
    Park R; Park JC
    Immunotherapy; 2021 Aug; 13(11):931-940. PubMed ID: 34100301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Revisiting the concept of neoadjuvant and induction therapy in head and neck cancer with the advent of immunotherapy.
    Smussi D; Mattavelli D; Paderno A; Gurizzan C; Lorini L; Romani C; Bignotti E; Grammatica A; Ravanelli M; Bossi P
    Cancer Treat Rev; 2023 Dec; 121():102644. PubMed ID: 37862833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and network meta-analysis.
    Wang S; Yan L; Yu J; Lu C
    Eur Arch Otorhinolaryngol; 2024 Jul; 281(7):3385-3395. PubMed ID: 38358507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of immune-related adverse events on survival among patients with head-and-neck squamous cell carcinoma.
    Elghawy O; Barsouk A; Patel R; Reed-Guy L; Wang JS; Xu J; Yang A; Sussman J; Kaur V
    Immunotherapy; 2024; 16(16-17):1069-1078. PubMed ID: 39392156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy.
    Rosenberg AJ; Perez CA; Guo W; de Oliveira Novaes JM; da Silva Reis KFO; McGarrah PW; Price KAR
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e433330. PubMed ID: 38718318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitor use in head and neck squamous cell carcinoma: the current landscape and future perspectives.
    Gatfield ER; Tadross J; Ince W
    Future Oncol; 2024; 20(23):1695-1711. PubMed ID: 38889284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial.
    Ferris RL; Spanos WC; Leidner R; Gonçalves A; Martens UM; Kyi C; Sharfman W; Chung CH; Devriese LA; Gauthier H; Chiosea SI; Vujanovic L; Taube JM; Stein JE; Li J; Li B; Chen T; Barrows A; Topalian SL
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging immune checkpoint inhibitors for the treatment of head and neck cancers.
    Green SE; McCusker MG; Mehra R
    Expert Opin Emerg Drugs; 2020 Dec; 25(4):501-514. PubMed ID: 33196319
    [No Abstract]   [Full Text] [Related]  

  • 19. Combining radiotherapy and immunotherapy in definitive treatment of head and neck squamous cell carcinoma: review of current clinical trials.
    Plavc G; Strojan P
    Radiol Oncol; 2020 Oct; 54(4):377-393. PubMed ID: 33064670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
    Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
    Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.